Project: Novel Parkinson's Disease therapy targeting iron-related cell death and alpha synuclein aggregation

Acronym PD-IRONSYN (Reference Number: 114370)
Duration 01/11/2020 - 01/11/2023
Project Topic We will deliver a first-in-class multifunction iron chelating compound (SP-420) as a disease-modifying therapy for Parkinson’s Disease (PD). SP-420 targets the accumulation of iron in order to reduce iron-related oxidative stress, cell death (ferroptosis) and alpha synuclein aggregation. SP-420 is considered to be superior (in efficacy and safety) to other iron chelators. Preclinical data for SP-420 as PD-therapy will be obtained, in order to start clinical testing 18 months after the project.
Network Eurostars 2
Call Eurostars Cut–off 13

Project partner

Number Name Role Country
1 Abfero Ltd Coordinator United Kingdom
2 Centre Hospitalier Universitaire de Lille Partner France
3 Erasmus Medical Center Partner Netherlands
4 Pronexus Analytical AB Partner Sweden